These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20707648)

  • 1. Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study.
    You D; Jeong IG; Kim SW; Chung BH; Cho JS; Lee HM; Yun SC; Kim CS
    Scand J Urol Nephrol; 2010 Dec; 44(6):399-405. PubMed ID: 20707648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
    Park J; Shin DW; Yun SJ; Park SW; Jeon SS; Kwak C; Kwon TG; Kim HJ; Ahn H
    Oncology; 2013; 85(5):299-305. PubMed ID: 24217330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.
    van Andel G; Bottomley A; Fosså SD; Efficace F; Coens C; Guerif S; Kynaston H; Gontero P; Thalmann G; Akdas A; D'Haese S; Aaronson NK
    Eur J Cancer; 2008 Nov; 44(16):2418-24. PubMed ID: 18774706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of high dose rate brachytherapy in combination with external beam radiotherapy on men's health-related quality of life and sexual function over a 2 year time span.
    Conaglen HM; de Jong D; Hartopeanu C; Conaglen JV; Tyrie LK
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):197-204. PubMed ID: 23183305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of quality of life and sexual functioning after laparoscopic total mesorectal excision.
    Breukink SO; van der Zaag-Loonen HJ; Bouma EM; Pierie JP; Hoff C; Wiggers T; Meijerink WJ
    Dis Colon Rectum; 2007 Feb; 50(2):147-55. PubMed ID: 17160572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification.
    Lips IM; van Gils CH; van der Heide UA; Kruger AE; van Vulpen M
    BJU Int; 2009 Mar; 103(6):762-7. PubMed ID: 18990145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
    Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
    J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
    Spry NA; Kristjanson L; Hooton B; Hayden L; Neerhut G; Gurney H; Corica T; Korbel E; Weinstein S; McCaul K
    Eur J Cancer; 2006 May; 42(8):1083-92. PubMed ID: 16632343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study.
    Lebret T; Culine S; Davin JL; Hennequin C; Mignard JP; Moreau JL; Rossi D; Zerbib M; Mahmoudi A; Latorzeff I
    Aging Male; 2014 Jun; 17(2):87-93. PubMed ID: 24576298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
    Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E
    BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Hammerer PG; Wirth MP;
    Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.